The findings could add momentum for F.D.A. authorization of the pediatric dose, perhaps as early as next week, a long-awaited development that would affect 28 million children.
Posted inBusiness
F.D.A. Says Pfizer Vaccine’s Benefits Outweigh Key Risks in Children 5 to 11
